Crossroads Strategies, LLC
Crossroads Strategies, LLC filed a Q3 report for Eisai, Inc. on October 17, 2026, reporting $50,000 in lobbying income.
Lobbying for Eisai, Inc. · human health care company
Issues related to tax reform; international taxation.
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing; H.R.6130, Alzheimers Screening and Prevention (ASAP) Act of 2025.